about
The pediatric microbiome and the lungClinical applications of pulmonary delivery of antibioticsThe Evolution of Cystic Fibrosis CareBackground and EpidemiologyOral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbationDesign and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosisPulmonary exacerbations in cystic fibrosis with negative bacterial cultures.Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbationsRole of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.State of progress in treating cystic fibrosis respiratory disease.Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis.Identification of neutrophil activation markers as novel surrogate markers of CF lung disease.Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onsetPhysical therapy management of a patient on portable extracorporeal membrane oxygenation as a bridge to lung transplantation: a case reportOutcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients.Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosisLong term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis.Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisOutcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung diseaseBronchiectasis in adults: a review.Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review.Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Putting lung function and physiology into perspective: cystic fibrosis in adults.The role of mean platelet volume predicting acute exacerbations of cystic fibrosis in children.Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.Short-term effects of high-frequency chest compression and positive expiratory pressure in patients with cystic fibrosisEarly detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis.Improving inpatient cystic fibrosis pulmonary exacerbation care: two success stories.Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis.
P2860
Q26851334-B8DC716B-3F20-4C2E-B48C-FA5394CEB0A9Q26996053-CE621047-3206-4D0F-A9B2-1FF43E882558Q26999299-F8E8DFE1-7360-44CA-996B-B82CB7997C12Q30248742-57F76C04-9309-4D2B-9002-F2FA096472FCQ33725822-F718E218-967F-4EC0-B48E-2AFA0BCCC2B0Q33744911-BB1B7D2B-5A73-4DE6-A5FD-D22EDB4E8056Q33836302-33DE460D-E400-4401-B0A5-CC06DDCEE2F8Q33943042-74C6283C-94AD-4256-8679-588753969E8FQ34118967-5B505FEC-221C-49AD-8442-400BCDCB7EC2Q34221582-FB622EAA-BE0E-429F-879F-171B3E930D3AQ34320262-FC9DA3EC-1AFB-4E9C-A78B-491C779D2AE0Q34375926-1B25798F-9BFA-40D5-B23D-C0A620C2ED3DQ34422248-2D148526-1725-4FFA-803C-B419C8596FFEQ34784319-8198629E-B38E-46A0-8C9C-5F98AF60101DQ35143420-6FA99018-B8E5-4A19-9041-9214DBDEE50BQ35777514-094C68E1-65AB-49BE-BAA9-808659E22804Q35801062-F777D067-D294-4468-9C27-8B03017C3127Q35876643-3EAB6799-9DA6-451B-B1AC-E29A03071BBDQ36031045-C8E25E3F-7D83-438C-9EFD-F271812AE354Q36184296-517F0CCC-7475-4638-A06D-6BD07D1F5E4FQ36295243-DC4E223F-46E5-4FC1-BED7-99A3DC46A793Q36771148-22DE8E20-DFF0-4521-B3A7-6126D1308802Q36827488-C6885E7B-A0AB-4FE2-8C1A-01DBBB54B7BFQ36891526-26FE8A73-18B8-4295-8B94-5D447C7392C2Q36960790-6CDB7E3F-76B4-477B-9001-F93743ECFEFAQ37282172-41BF3771-7EED-45B9-BD4C-3C6D8BE93B5AQ37377689-40C5E76E-E570-4143-BD78-21843F8EE2BDQ37752239-7CBD3163-7F02-4EB8-B150-E2C82325E111Q38037076-2086E968-0C86-49B8-9CA8-DC39E96EF8E2Q38248996-7F10CFCD-16FF-4D37-B778-5C3A2D9855B7Q38596522-8E7282B0-8827-4497-8657-9970F0BCF317Q38688865-4E193FD1-98F2-4999-B7B2-46DAEF4C9F18Q38765336-FF5B1F1D-14BC-4279-A9CF-3D5A55107CA1Q39800405-3BF2CEA9-50C5-4614-A9BB-C1EAE88757F4Q41117268-D8C0B918-4771-4879-8DBC-BA5794D1A39EQ42011378-BED0CA5B-091A-4DC7-A647-6EE8F4A29995Q43200814-1EA47052-504B-49EA-98E2-23E19FD5145AQ43770588-275EC411-FCF1-4713-AB98-066174453DE6Q44063856-9684C853-3DF5-44F0-9DEE-13AC3ACC83B8Q45942214-86E7BFF9-543B-4AE5-B203-67B9BCF42683
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Cystic fibrosis pulmonary exacerbations.
@ast
Cystic fibrosis pulmonary exacerbations.
@en
type
label
Cystic fibrosis pulmonary exacerbations.
@ast
Cystic fibrosis pulmonary exacerbations.
@en
prefLabel
Cystic fibrosis pulmonary exacerbations.
@ast
Cystic fibrosis pulmonary exacerbations.
@en
P1476
Cystic fibrosis pulmonary exacerbations.
@en
P2093
Margaret Rosenfeld
Thomas Ferkol
P304
P356
10.1016/J.JPEDS.2005.10.019
P407
P50
P577
2006-02-01T00:00:00Z